A retrospective study of adults with type 2 diabetes found that increasing Ozempic doses was associated with a lower risk of major adverse cardiovascular events than switching to Mounjaro.

A real-world study of 636,525 adults with type 2 diabetes suggests that patients who increased their Ozempic dose to 2 mg experienced a 6% lower risk of major adverse cardiovascular events (MACE) compared to those who switched to Mounjaro. The analysis, known as the COMPETE SWITCH Cardiovascular (CV) analysis, utilized data from the Komodo Health Healthcare Map to track outcomes for patients previously on 1 mg of semaglutide weekly.

Study Methodology and Findings

The research examined 185,705 individuals who increased their semaglutide dose and 23,104 who switched to tirzepatide. MACE outcomes tracked in the study included all-cause death, myocardial infarction, and stroke. Researchers noted that because the study was observational and retrospective, it demonstrates an association rather than causation, and further research is required to compare the cardiovascular benefits of the two medications.

Expert Perspectives on Medication Management

Medical experts noted that the findings might be influenced by factors such as medication adherence and the time required for patients to adjust to new treatments. While both Ozempic and Mounjaro are GLP-1 medications, they function through different pathways; semaglutide is a direct GLP-1 receptor agonist, while tirzepatide acts as a dual agonist of both GIP and GLP-1 receptors. Physicians emphasize that treatment decisions should be individualized based on patient tolerance, health goals, and side effects.